Dysregulated incretin signaling also affects hepatic gluconeogenesis and lipid metabolism, contributing to the increased prevalence of non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome in PCOS patients [230,231,232]. The gene discussed is GCG; the disease is metabolic dysfunction-associated steatotic liver disease.